Published in Antimicrob Agents Chemother on July 01, 1994
Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother (1995) 0.94
The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes. PLoS One (2013) 0.85
Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy. Antimicrob Agents Chemother (1996) 0.79
Sanctuary growth of human immunodeficiency virus in the presence of 3'-azido-3'-deoxythymidine. J Virol (1995) 0.79
Effect of zidovudine on the primary cytolytic T-lymphocyte response and T-cell effector function. Antimicrob Agents Chemother (2000) 0.76
Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine. Antimicrob Agents Chemother (2004) 0.75
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer (1974) 6.53
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Simple, quantitative assay for both xenotropic murine leukemia and ecotropic feline leukemia viruses. J Virol (1974) 2.84
Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells. Proc Natl Acad Sci U S A (1989) 2.66
Kinetics of pharmacologic response. Pharmacol Ther (1982) 2.21
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol (1987) 2.10
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med (1988) 2.08
Failed prophylactic zidovudine after needlestick injury. Lancet (1990) 2.00
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A (1987) 1.96
Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem (1987) 1.94
Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med (1987) 1.88
3'-Azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res (1987) 1.67
Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. Mol Pharmacol (1989) 1.54
The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol (1988) 1.45
Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol (1988) 1.38
Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem (1988) 1.32
3'-azido-3'-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem (1987) 1.32
Purine nucleobase transport in human erythrocytes. Reinvestigation with a novel "inhibitor-stop" assay. J Biol Chem (1988) 1.09
Acquired immunodeficiency syndrome-associated arthritis. Am J Med (1988) 1.09
Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. Mol Pharmacol (1991) 1.03
Infection of human fibroblasts and osteoblast-like cells with HIV-1. AIDS (1990) 1.00
Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats. J Pharm Sci (1989) 0.95
Extraction of intracellular nucleosides and nucleotides with acetonitrile. Clin Chem (1989) 0.86
Inhibition by AZT of HIV-1 replication in acutely infected U-937 cells. J Leukoc Biol (1990) 0.84
In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrob Agents Chemother (1990) 0.83
Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob Agents Chemother (1992) 0.80
Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody. AIDS Res Hum Retroviruses (1990) 0.79
Prophylactic and therapeutic effects of phosphonoformate against feline leukemia virus in vitro. Am J Vet Res (1991) 0.77
Evaluation of antiviral activity and toxicity of dextran sulfate in feline leukemia virus-infected cats. Antimicrob Agents Chemother (1991) 0.77
Zidovudine prophylaxis following exposure to human immunodeficiency virus. J Gen Intern Med (1990) 0.77
Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukemia virus. Cancer Res (1979) 1.56
Long-term follow-up on an intensified treatment regimen for advanced resectable head and neck squamous cell carcinomas. Cancer Invest (2001) 1.40
Abrogation of lymphocyte blastogenesis by a feline leukaemia virus protein. Nature (1978) 1.39
Partial dissociation of subgroup C phenotype and in vivo behaviour in feline leukaemia viruses with chimeric envelope genes. J Gen Virol (1992) 1.33
Pathogenesis of experimental feline leukemia virus infection. J Natl Cancer Inst (1979) 1.33
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A (2000) 1.32
Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther (1999) 1.32
Inhibition of concanavalin A stimulation of feline lymphocytes by inactivated feline leukemia virus. Cancer Res (1977) 1.24
Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther (2001) 1.20
Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines. J Immunol (1985) 1.19
Protection against feline leukemia by vaccination with a subunit vaccine. Infect Immun (1981) 1.16
Lymphocytotoxic strains of feline leukemia virus induce apoptosis in feline T4-thymic lymphoma cells. Lab Invest (1992) 1.16
Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther (2000) 1.16
Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res (1982) 1.14
Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci (2001) 1.06
Abrogation of resistance to feline oncornavirus disease by immunization with killed feline leukemia virus. Cancer Res (1977) 1.05
Modifications of the immunofluorescence assay for feline leukemia virus group-specific antigens. Am J Vet Res (1978) 1.03
Feline leukemia virus infection: age-related variation in response of cats to experimental infection. J Natl Cancer Inst (1976) 1.03
Purification of infectious feline leukemia virus from large volumes of tissue culture fluids. J Clin Microbiol (1977) 1.01
A feline large granular lymphoma and its derived cell line. In Vitro Cell Dev Biol (1990) 0.98
Serological and virological evidence of human T-lymphotropic virus in systemic lupus erythematosus. Med Microbiol Immunol (1987) 0.97
Inhibition of human lymphocyte mitogen and antigen response by a 15,000-dalton protein from feline leukemia virus. Cancer Res (1979) 0.97
Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther (2001) 0.97
Pathogenicity induced by feline leukemia virus, Rickard strain, subgroup A plasmid DNA (pFRA). J Virol (1998) 0.97
Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther (2001) 0.94
Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res (2001) 0.94
Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs (2001) 0.94
Immunization against feline oncarnavirus disease using a killed tumor cell vaccine. Cancer Res (1976) 0.92
Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin Cancer Res (2001) 0.92
Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol (1999) 0.92
Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats. J Acquir Immune Defic Syndr (1993) 0.92
Mobility of lymphocyte surface membrane concanavalin A receptors of normal and feline leukemia virus-infected viremic felines. Cancer Res (1979) 0.91
Differential pathogenicity of two feline leukemia virus subgroup A molecular clones, pFRA and pF6A. J Virol (2000) 0.90
Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res (1991) 0.90
Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res (1991) 0.90
Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus. Antimicrob Agents Chemother (2000) 0.89
Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Clin Cancer Res (1998) 0.89
A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. Pharm Res (1991) 0.88
Passive immunity to feline leukemia: evaluation of immunity from dams naturally infected and experimentally vaccinated. Infect Immun (1977) 0.88
Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats. Antimicrob Agents Chemother (1992) 0.88
Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol (1997) 0.88
Detection of feline leukemia virus in tissues of cats by a paraffin embedding immunofluorescence procedure. J Natl Cancer Inst (1978) 0.87
Suppression of in vitro neutrophil function by feline leukaemia virus (FeLV) and purified FeLV-p15E. J Gen Virol (1987) 0.87
Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep (1979) 0.86
Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res (1998) 0.86
The feline model of neuroAIDS: understanding the progression towards AIDS dementia. J Psychopharmacol (2000) 0.86
Early suppression of viremia by ZDV does not alter the spread of feline immunodeficiency virus infection in cats. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.86
Retrovirus-mediated immunosuppression. II. FeLV-UV alters in vitro murine T lymphocyte behavior by reversibly impairing lymphokine secretion. J Immunol (1985) 0.86
Neurophysiologic and immunologic abnormalities associated with feline immunodeficiency virus molecular clone FIV-PPR DNA inoculation. J Acquir Immune Defic Syndr (2000) 0.86
Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors. Pharm Res (1998) 0.86
Cytostatic and apoptotic effects of paclitaxel in human breast tumors. Cancer Chemother Pharmacol (1998) 0.86
Relationship between feline leukemia virus antigen expression and viral infectivity in blood, bone marrow, and saliva of cats. Cancer Res (1977) 0.85
Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res (1991) 0.85
In vivo evolution and selection of recombinant feline leukemia virus species. Virus Res (1998) 0.85
Pharmacodynamics of doxorubicin in human prostate tumors. Clin Cancer Res (1998) 0.85
2',3'-Dideoxyinosine is not metabolized in human placenta. Drug Metab Dispos (1993) 0.85
A technique for continuous intravenous infusion in cats. Lab Anim Sci (1989) 0.85
Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol (1993) 0.84
Pharmacodynamics of taxol in human head and neck tumors. Cancer Res (1996) 0.84
Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro. Antiviral Res (1992) 0.84
Penetration of mitomycin C in human bladder. Cancer Res (1993) 0.84
Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures. Pharm Res (1998) 0.84
Recombination between feline exogenous and endogenous retroviral sequences generates tropism for cerebral endothelial cells. Am J Pathol (1994) 0.84
Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switching. J Chromatogr B Biomed Appl (1995) 0.83
Gastrointestinal and hepatic first-pass elimination of 2',3'-dideoxyinosine in rats. J Pharmacol Exp Ther (1993) 0.83
Feline leukemia virus variants in experimentally induced thymic lymphosarcomas. Virology (1995) 0.83
In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrob Agents Chemother (1990) 0.83
Frontal lobe neuronal injury correlates to altered function in FIV-infected cats. J Acquir Immune Defic Syndr (1999) 0.82
Infectious feline leukaemia virus is erythrosuppressive in vitro. Leuk Res (1986) 0.82
Telomere amount and length assay. Pharm Res (2001) 0.82
Experimental oncornavirus vaccines in the cat. Cancer Res (1976) 0.82
SV40 Immortalization of feline fibroblasts as targets for MHC-restricted cytotoxic T-cell assays. Vet Immunol Immunopathol (2001) 0.82
Inhibition of erythroid colony-forming cells by a Mr 15,000 protein of feline leukemia virus. Cancer Res (1984) 0.82
A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol (2000) 0.82
Influence of culture conditions of growth of FL-74 cells and feline oncornavirus cell membrane associated antigen production. In Vitro (1976) 0.82
Immunoglobulin class response to canine distemper virus in gnotobiotic dogs. Vet Immunol Immunopathol (1983) 0.82
Influence of adrenal corticosteroids on the susceptibility of cats to feline leukemia virus infection. Cancer Res (1979) 0.82
Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. Pharm Res (1996) 0.81
Prevalence of disease in nonviremic cats previously exposed to feline leukemia virus. J Am Vet Med Assoc (1990) 0.81
Design and analysis of in vitro antitumor pharmacodynamic studies. Cancer Res (1995) 0.81
Feline oncornavirus-associated cell membrane antigen. VI. Cytotoxic antibody in cats exposed to feline leukemia virus. J Natl Cancer Inst (1976) 0.81
Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics. Pharm Res (1996) 0.81
Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum. Pharm Res (1993) 0.81
In vitro replication and cytopathogenicity of the feline immunodeficiency virus for feline T4 thymic lymphoma 3201 cells. Virology (1990) 0.81
Effects of whole blood lysis and fixation on the infectivity of human T-lymphotropic virus type 1 (HTLV-I). Cytometry (1994) 0.81
Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol (1996) 0.80
Biologic and immunologic response of cats to experimental infection with feline leukemia virus. Bibl Haematol (1975) 0.80
Effect of interstitial cystitis on drug absorption from urinary bladder. J Pharmacol Exp Ther (1994) 0.80
Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. Cancer Chemother Pharmacol (1999) 0.80
Pharmacokinetics of oral 2',3'-dideoxyinosine in rats. Pharm Res (1992) 0.80
Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. J Urol (1994) 0.80
Detection of simian T-lymphotropic virus type I using the polymerase chain reaction. Int J Cancer (1992) 0.80
Recovery of soluble feline oncornavirus-associated cell membrane antigen from large volumes of tissue culture fluids. J Immunol Methods (1979) 0.80
Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci (1996) 0.80
Hydroxylated metabolies of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits. Cancer Res (1978) 0.80
Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine. Clin Cancer Res (1997) 0.80
The effects of perfluorodecanoic acid (PFDA) on humoral, cellular, and innate immunity in Fischer 344 rats. Immunopharmacol Immunotoxicol (1992) 0.79
Feline leukemia virus: current status of the feline induced immune depression and immunoprevention. Cancer Metastasis Rev (1987) 0.79
Penetration kinetics of 2',3'-dideoxyinosine in dermis is described by the distributed model. Pharm Res (1995) 0.79
Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone. Cancer Res (1980) 0.79